FAP and neoplasm: To resolve this problem, we adopted a simplified approach involving a single-stain IHC evaluation of FAP+ CAFs, which are widely recognized as a tumor-promoting and immunosuppressive subtype of CAFs closely associated with tumor progression and poor clinical outcomes [19,20,43,44,45].